Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine

Expert Review of Vaccines

Volumn 9, Issue 12, 2010, Pages 1385-1398

  Walker, Woolf T ^a,b   Faust, Saul N ^a,b,c  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c University Hospital Southampton NHS Foundation Trust   (United Kingdom)

Author keywords

adjuvant; AS03; Guillain Barr syndrome; immunogenicity; pandemic H1N1 influenza; reactogenicity; squalene; swine flu; thiomersal

Indexed keywords

ALPHA TOCOPHEROL; AREPANRIX; HUMENZA; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; PANVAX; POLYSORBATE 80; SQUALENE; THIOMERSAL; UNCLASSIFIED DRUG;

ARTHRALGIA; DISEASE SURVEILLANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG SAFETY; FATIGUE; FEBRILE CONVULSION; FEEDING; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREACTIVITY; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MASS IMMUNIZATION; MYALGIA; NAUSEA; PAIN; PANDEMIC INFLUENZA; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEASONAL INFLUENZA; SEROCONVERSION; SIDE EFFECT; SINGLE DRUG DOSE; SWELLING; UNSPECIFIED SIDE EFFECT; VIRION; VOMITING;

ALPHA-TOCOPHEROL; DRUG COMBINATIONS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; POLYSORBATES; SQUALENE; VACCINES, INACTIVATED; VACCINES, SUBUNIT;

EID: 78649493970     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.141     Document Type: Review

References (100)

1. Cox NJ, Fukuda K. Infuenza. Infect. Dis. Clin. North Am. 12(1), 27-38 (1998).
2. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of infuenza A viruses. Microbiol. Rev. 56(1), 152-179 (1992).
3. Dawood FS, Jain S, Finelli L et al. Emergence of a novel swine-origin infuenza A (H1N1) virus in humans. N. Engl. J. Med. 360(25), 2605-2615 (2009).
4. Smith GJ, Vijaykrishna D, Bahl J et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 infuenza A epidemic. Nature 459(7250), 1122-1125 (2009).
5. Garten RJ, Davis CT, Russell CA et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) infuenza viruses circulating in humans. Science 325(5937), 197-201 (2009).
6. Khazeni N, Hutton DW, Garber AM, Owens DK. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an infuenza A (H5N1) pandemic. Ann. Intern. Med. 151(12), 840-853 (2009).
7. Germann TC, Kadau K, Longini IM Jr, Macken CA. Mitigation strategies for pandemic infuenza in the United States. Proc. Natl Acad. Sci. USA 103(15), 5935-5940 (2006).
8. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S et al. Pneumonia and respiratory failure from swine-origin infuenza A (H1N1) in Mexico. N. Engl. J. Med. 361(7), 680-689 (2009).
9. Chan M. World now at the start of 2009 infuenza pandemic: World Health Organization, Geneva, Switzerland (2009
10. Kilbourne ED. Infuenza pandemics of the 20th Century. Emerg. Infect. Dis. 12(1), 9-14 (2006).
11. Patterson KD, Pyle GF. The geography and mortality of the 1918 infuenza pandemic. Bull. Hist. Med. 65(1), 4-21 (1991).
12. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 'Spanish' infuenza pandemic. Bull. Hist. Med. 76(1), 105-115 (2002).
13. Taubenberger JK, Morens DM. 1918 infuenza: the mother of all pandemics. Emerg. Infect. Dis. 12(1), 15-22 (2006).
14. Guleria R, Kumar J, Mohan A, Wig N. Infuenza A: from highly pathogenic H5N1 to pandemic 2009 H1N1. Epidemiology and clinical features. Indian J. Microbiol. 49, 315-319 (2009).
15. Chotpitayasunondh T, Lochindarat S, Srisan P et al. Cases of infuenza A (H5N1)-Thailand, 2004. MMWR Morb. Mortal. Wkly Rep. 53(5), 100-103 (2004).
16. World Health Organization. H5N1 avian infuenza: frst steps towards development of a human vaccine. Wkly Epidemiol. Rec. 80(33), 277-278 (2005).
17. Thompson WW, Shay DK, Weintraub E et al. Infuenza-associated hospitalizations in the United States. JAMA 292(11), 1333-1340 (2004).
18. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with infuenza and respiratory syncytial virus in the United States. JAMA 289(2), 179-186 (2003).
19. Bautista E, Chotpitayasunondh T, Gao Z et al. Clinical aspects of pandemic 2009 infuenza A (H1N1) virus infection. N. Engl. J. Med. 362(18), 1708-1719 (2010).
20. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic infuenza A H1N1 infection in England: a cross-sectional serological study. Lancet 375 (9270), 1100-1108 (2010).
21. Donaldson LJ, Rutter PD, Ellis BM et al. Mortality from pandemic A/H1N1 2009 infuenza in England: public health surveillance study. Br. Med. J. 339, b5213 (2009).
22. Echevarria-Zuno S, Mejia-Arangure JM, Mar-Obeso AJ et al. Infection and death from infuenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 374(9707), 2072-2079 (2009).
23. Viboud C, Miller M, Olson D, Osterholm M, Simonsen L. Preliminary estimates of mortality and years of life lost associated with the 2009 A/H1N1 pandemic in the US and comparison with past infuenza seasons. PLoS Curr. Infuenza RRN1153 (2010).
24. Bishop JF, Murnane MP, Owen R. Australia's winter with the 2009 pandemic infuenza A (H1N1) virus. N. Engl. J. Med. 361(27), 2591-2594 (2009).
25. Kuehn BM. CDC names H1N1 vaccine priority groups. JAMA 302(11), 1157-1158 (2009).
26. Jain S, Kamimoto L, Bramley AM et al. Hospitalized patients with 2009 H1N1 infuenza in the United States, April-June 2009. N. Engl. J. Med. 361(20), 1935-1944 (2009).
27. Hancock K, Veguilla V, Lu X et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 infuenza virus. N. Engl. J. Med. 361(20), 1945-1952 (2009).
28. Surveillance for pediatric deaths associated with 2009 pandemic infuenza A (H1N1) virus infection-United States, April-August 2009. MMWR Morb. Mortal. Wkly Rep. 58(34), 941-947 (2009).
29. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing infuenza in healthy children. Cochrane Database Syst. Rev. 2, CD004879 (2008).
30. Bresson JL, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion infuenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet 367(9523), 1657-1664 (2006).
31. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion infuenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343-1351 (2006).
32. Liang XF, Wang HQ, Wang JZ et al. Safety and immunogenicity of 2009 pandemic infuenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 375(9708), 55-66 (2009).
33. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 infuenza A H1N1 in USA: a preliminary report of two randomised controlled Phase 2 trials. Lancet 375(9708), 41-48 (2009).
34. Nolan T, McVernon J, Skeljo M et al. Immunogenicity of a monovalent 2009 infuenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 303(1), 37-46 (2010).
35. Leroux-Roels I, Roman F, Forgus S et al. Priming with AS03 A-adjuvanted H5N1 infuenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 28(3), 849-857 (2010).
36. Waddington CS, Walker WT, Oeser C et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 infuenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. Br. Med. J. 340, c2649 (2010).
37. Carmona A, Omenaca F, Tejedor JC et al. Immunogenicity and safety of AS03-adjuvanted 2009 infuenza A H1N1 vaccine in children 6-35 months. Vaccine 28(36), 5837-5844 (2010).
38. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of infuenza A H1N1v 2009 vaccine formulated with and without AS03 (A)-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 28(7), 1740-1745 (2010).
39. Schwarz TF, Horacek T, Knuf M et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 27(45), 6284-6290 (2009).
40. Fiore AE, Neuzil KM. 2009 infuenza A(H1N1) monovalent vaccines for children. JAMA 303(1), 73-74 (2010).
41. Collin N, de Radigues X. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 infuenza. Vaccine 27(38), 5184-5186 (2009
42. Pandemic infuenza A (H1N1) 2009 virus vaccine-conclusions and recommendations from the October 2009 meeting of the immunization Strategic Advisory Group of Experts. Wkly Epidemiol. Rec. 84(49), 505-508 (2009).
43. Dalton I. (H1N1) Swine Flu Infuenza: Phase Two of the Vaccination Programme; Children Over 6 Months and Under 5 Years. Department of Health, London, UK (2009).
44. GlaxoSmithKline. Real-life experience with the H1N1 2009 pandemic: new data on vaccines and antivirals. Presented at: Options for the Control of Infuenza VII. Hong Kong SAR, China, 3-7 September 2010.
45. EMEA. CHMP Assessment Report for Pandemrix. European Medicines Agency (2009).
46. EMEA. European Medicines Agency recommends authorisation of two vaccines for infuenza pandemic (H1N1) 2009. European Medicines Agency (2009).
47. WHO. Summary of available candidate vaccine viruses for development of Pandemic (H1N1) 2009 virus vaccines. World Health Organization, Geneva, Switzerland (2009).
48. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine 26(26), 3209-3222 (2008).
49. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted infuenza vaccines: integrated analysis from a large safety database. Vaccine 27(49), 6959-6965 (2009).
50. Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic infuenza vaccine: a randomised controlled trial. Lancet 370(9587), 580-589 (2007).
51. Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic infuenza vaccine. PLoS One 3(2), e1665 (2008).
52. Chu DW, Hwang SJ, Lim FS et al. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic infuenza vaccine: a Phase III study in a large population of Asian adults. Vaccine 27(52), 7428-7435 (2009).
53. Rumke HC, Bayas JM, de Juanes JR et al. Safety and reactogenicity profle of an adjuvanted H5N1 pandemic candidate vaccine in adults within a Phase III safety trial. Vaccine 26(19), 2378-2388 (2008).
54. Newmark HL. Squalene, olive oil, and cancer risk. Review and hypothesis. Ann. NY Acad. Sci. 889, 193-203 (1999).
55. Dupuis M, Denis-Mize K, LaBarbara A et al. Immunization with the adjuvant MF59 induces macrophage traffcking and apoptosis. Eur. J. Immunol. 31(10), 2910-2918 (2001).
56. Alving CR, Grabenstein JD. Re: antibodies to squalene in Gulf War Syndrome. Exp. Mol. Pathol. 68(3), 196-198 (2000).
57. Phillips CJ, Matyas GR, Hansen CJ, Alving CR, Smith TC, Ryan MA. Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness. Vaccine 27(29), 3921-3926 (2009).
58. Lippi G, Targher G, Franchini M. Vaccination, squalene and anti-squalene antibodies: facts or fction? Eur. J. Intern. Med. 21(2), 70-73 (2010).
59. Chan K-C. Gulf War illnesses: questions about the presence of squalene antibodies in veterans can be resolved. United States General Accounting Offce, Washington, DC, USA (1999).
60. Clark T W, Pareek M, Hoschler K et al. Trial of 2009 infuenza A (H1N1) monovalent MF59-adjuvanted vaccine. N. Engl. J. Med. 361(25), 2424-2435 (2009).
61. Global Advisory Committee on Vaccine Safety, 6-7 June 2006. Wkly Epidemiol. Rec. 81 (28) 273-278 (2006).
62. Offt PA. Thimerosal and vaccines-a cautionary tale. N. Engl. J. Med. 357(13), 1278-1279 (2007).
63. Heron J, Golding J. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United Kingdom does not support a causal association. Pediatrics 114(3), 577-583 (2004).
64. Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal association. Pediatrics 114(3), 584-591 (2004).
65. Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics 118(1), e139-e150 (2006).
66. Thompson W W, Price C, Goodson B, Shay DK, Benson P, Hinrichsen VL et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N. Engl. J. Med. 357(13), 1281-1292 (2007).
67. Yess NJ. U.S. Food and Drug Administration survey of methyl mercury in canned tuna. J. AOAC Int. 76(1), 36-38 (1993).
68. Pichichero ME, Gentile A, Giglio N et al. Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines. Pediatrics 121(2), e208-e214 (2008).
69. Clarkson T W, Magos L. The toxicology of mercury and its chemical compounds. Crit. Rev. Toxicol. 36(8), 609-662 (2006).
70. Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet 360(9347), 1737-1741 (2002).
71. Erlewyn-Lajeunesse M, Brathwaite N, Lucas JS, Warner JO. Recommendations for the administration of infuenza vaccine in children allergic to egg. Br. Med. J. 339, b3680 (2009).
72. Bohlke K, Davis RL, Marcy SM et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 112(4), 815-820 (2003).
73. Peng MM, Jick H. A population-based study of the incidence, cause, and severity of anaphylaxis in the United Kingdom. Arch. Intern. Med. 164(3), 317-319 (2004).
74. Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic infuenza A H1N1 vaccine when administered alone or simultaneously with the seasonal infuenza vaccine for the 2009-2010 infuenza season: a multicentre, randomised controlled trial. Lancet 375(9708), 49-55 (2010).
75. Gasparini R, Schioppa F, Lattanzi M et al. Impact of prior or concomitant seasonal infuenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int. J. Clin. Pract. 64(4), 432-438 (2010).
76. Walker WT, Andrews N, Waddington C et al. Relationships between reactogenicity and age, dose number and immunogenicity in 937 children receiving 2 doses of AS03B-adjuvanted split virion or whole virus H1N1 infuenza A 2009 pandemic vaccines. Presented at: Options for the Control of Infuenza VII. Hong Kong SAR, China, 3-7 September 2010 (p 80).
77. Yung C, Andrews N, Waight P, Hoschler K, Miller E. Age-specifc effectiveness and immunogenicity of an oil-in-water adjuvanted paendemic (H1N1) 2009 vaccine in high risk groups in England. Presented at: Options for the Control of Infuenza VII. Hong Kong SAR, China, 3-7 September 2010 (p 75).
78. Kelly H, Barr I. Large trials confrm immunogenicity of H1N1 vaccines. Lancet 375(9708), 6-9 (2010).
79. Van Buynder PG, Dhaliwal JK, Van Buynder JL et al. Protective effect of single-dose adjuvanted pandemic infuenza vaccine in children. Infuenza Other Respi. Viruses 4(4), 171-178 (2010).
80. Wichmann O, Stocker P, Poggensee G et al. Pandemic infuenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill. 15(18) pii: 19561 (2010).
81. Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenamin J. Vaccine effectiveness in pandemic infuenza-primary care reporting (VIPER), an observational study to assess the effectiveness of the pandemic infuenza A (H 1N 1)v vaccine. Health Technol. Assess. 14(34), 313-346 (2010).
82. MHRA. Final public statement-UK Suspected Adverse Reaction Analysis: Swine Flu (H1N1) Vaccines-Celvapan and Pandemrix. 26 March 2010: MHRA2010 1 April 2010.
83. Vesikari T. Hot topics in vaccines. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12-15 September 2010.
84. Louie JK, Acosta M, Jamieson DJ, Honein MA. Severe 2009 H1N1 infuenza in pregnant and postpartum women in California. N. Engl. J. Med. 362(1), 27-35 (2010).
85. Jamieson DJ, Honein MA, Rasmussen SA et al. H1N1 2009 infuenza virus infection during pregnancy in the USA. Lancet 374(9688), 451-458 (2009).
86. Nguyen-Van-Tam JS, Openshaw PJ, Hashim A et al. Risk factors for hospitalisation and poor outcome with pandemic A/H 1N 1 infuenza: United Kingdom frst wave (May-September 2009). Thorax 65(7), 645-651 (2010).
87. Zaman K, Roy E, Arifeen SE et al. Effectiveness of maternal infuenza immunization in mothers and infants. N. Engl. J. Med. 359(15), 1555-1564 (2008).
88. Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barre syndrome. Drug Saf 32(4), 309-323 (2009).
89. Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with infuenza vaccine and infuenza like illness using the United Kingdom General Practice Research Database. Am. J. Epidemiol. 169(3), 382-388 (2009).
90. Viray M, Wise M, Sejvar J et al. Active population-based surveillance among 45 million people in the US for Guillain-Barre syndrome following introduction of infuenza A(H1N1) 2009 monovalent vaccination, October 2009-March 2010. Presented at: Options for the Control of Infuenza VII. Hong Kong SAR, China, 3-7 September 2010 (p 76).
91. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ et al. Guillain-Barre syndrome following vaccination in the national infuenza immunization program, United States, 1976-1977. Am. J. Epidemiol. 110(2), 105-123 (1979).
92. MPA. Final summary of adverse drug reaction reports in Sweden with Pandemrix through October 2009-mid April 2010. Lakemedelsverket Medical Products Agency, Uppsala, Sweden (2010).
93. Booy R, Brown LE, Grohmann GS, Macintyre CR. Pandemic vaccines: promises and pitfalls. Med. J. Aust. 185(10 Suppl.), S62-S65 (2006).
94. Johansen K, Nicoll A, Ciancio BC, Kramarz P. Pandemic infuenza A(H1N1) 2009 vaccines in the European Union. Euro Surveill. 14(41), 19361 (2009).
95. ECDC in collaboration with the VAESCO consortium to develop a complementary tool for vaccine safety monitoring in Europe. Euro Surveill. 14(39) pii: 19345 (2009).
96. Strategic Advisory Group of Experts on Immunization-report of the extraordinary meeting on the infuenza A (H1N1) 2009 pandemic, 7 July 2009. Wkly Epidemiol. Rec. 84 (30) 301-304 (2009).
97. Vesikari T, Pellegrini M, Karvonen A et al. Enhanced immunogenicity of seasonal infuenza vaccines in young children using MF59 adjuvant. Pediatr. Infect. Dis. J. 28(7), 563-571 (2009).
98. Steel J, Lowen A, Wang T et al. An infuenza vaccine based on the conserved hemagglutinin stalk domain. Presented at: Options for the Control of Infuenza VII. Hong Kong SAR, China, 3-7 September 2010 (p 82).
99. Barr IG, McCauley J, Cox N et al. Epidemiological, antigenic and genetic characteristics of seasonal infuenza A(H1N1), A(H3N2) and B infuenza viruses: basis for the WHO recommendation on the composition of infuenza vaccines for use in the 2009-2010 Northern Hemisphere season. Vaccine 28(5), 1156-1167 (2010).
100. Nauta JJ, de Bruijn IA. The European CHMP criteria for infuenza vaccine immunogenicity cannot be improved by the use of confdence intervals. Vaccine 24(44-46), 6643-6644 (2006).